Log In
BCIQ
Print this Print this
 

Affimer

  Manage Alerts
Collapse Summary General Information
Company Avacta Group plc
DescriptionFragment crystallisable (Fc) region of an antibody fusions against programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionProgrammed cell death 1 (PD-1) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today